-59%

est. 2Y upside i

HealthcareSeries A

Medical coding automation

Rank

#415

Sector

HealthTech

Est. Liquidity

~3Y

Data Quality

Data: Medium

Arintra presents a strong upside opportunity for a job seeker, driven by its high growth rate (43% YoY), excellent gross margins (~75%), and position in a large, underserved HealthTech market with significant pain points.

Last updated: March 10, 2026

Bull (30%)+350%

Arintra significantly expands its market share by leveraging its GenAI and deep EHR integrations to offer a comprehensive revenue assurance platform, including advanced CDI and denial prevention. This drives revenue to over $100M by 2028, justifying a $450M+ valuation at a premium multiple, well above the current $100M.

Base (35%)+125%

Arintra continues its strong growth trajectory, securing more large health system customers and expanding its product features. It achieves a successful Series B or C round, or an acquisition, at a valuation of approximately $225M, representing a solid return for early equity holders.

Bear (35%)-75%

Dominant EHR incumbents like Epic or Cerner launch highly competitive, integrated autonomous coding solutions, or a well-funded competitor gains significant traction. Arintra's growth slows, leading to a down round or an acquisition at a valuation of $25M or less, severely impacting common stock value due to liquidation preferences.

Est. time to liquidity~3.0 years

Preference Stack Risk

high

Investors hold $21.5M in liquidation preferences ahead of common stock, representing 21.5% of the current $100M valuation.

Dilution Risk

moderate

As a Series A company, Arintra will likely raise additional funding rounds (Series B, C, etc.), which will lead to further dilution for existing equity holders.

Secondary Liquidity

none

As an early-stage, privately held company, there is currently no active secondary market or tender offers for Arintra's equity.

Other — 1 role

View all 1 open roles at Arintra →

Last updated: March 10, 2026

Questions to Ask at the Interview

Strategic questions based on Arintra's data — designed to show you've done your homework.

  • 1

    “Given the 'medium' incumbent threat from major EHR providers like Epic and Cerner, what is Arintra's long-term strategy to maintain and grow its competitive moat against these powerful players, especially as you expand into broader revenue assurance?”

  • 2

    “Arintra is expanding beyond autonomous medical coding into broader revenue assurance, including CDI and denial prevention. What are the key product development priorities and market segments for this expansion over the next 12-24 months?”

  • 3

    “With a Series A funding round completed at a $100M valuation, how is the company thinking about a liquidity event timeline for employees, and what are the key milestones Arintra aims to achieve in the next 2-3 years to get there?”

Community

Valuation Sentiment

Our model estimates -59% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

0/2000

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.